Transaction DateRecipientSharesTypePriceValue
28th August 2020Jeremy M Levin8,488Open or private purchase$5.84$49,569.92
8th October 2019Jeremy M Levin60,000Open or private purchase$2.50$150,000.00
8th October 2019Pharmaceutical Co Ltd Takeda2,000,000Open or private purchase$2.50$5,000,000.00
26th February 2019Karen Bernstein10,000Open or private purchase$2.02$20,210.00
22nd February 2019Jeremy M Levin75,000Open or private purchase$2.00$150,000.00
Ovid Therapeutics
Ovid Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Ovid Therapeutics, Inc. focuses on developing medicines for patients with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.


Ticker: OVID
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1636651
Employees: 59
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals